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Abstract
Food allergies are increasing in prevalence and present an emerging epidemic for westernized
countries. Strict dietary avoidance is the only approved management for food allergy, but
accidental exposures regularly occur, leading to significant patient anxiety and decreased quality
of life. Over the past decade, oral and sublingual immunotherapies have emerged as potential
treatments for food allergy. While several small clinical trials have demonstrated that
immunotherapy can desensitize food-allergic individuals, strategies for further enhancing safety
and definitively establishing long-term efficacy are needed. This review presents an overview of
recent oral and sublingual immunotherapy trials, and provides a glimpse into what the next
generation of food immunotherapy may entail.
Introduction
Food allergy (FA) is a serious disorder that has life-altering implications for afflicted
individuals and their families. Although FA can encompass several different disease entities,
here we use the term to denote an immunoglobulin E (IgE)-mediated hypersensitivity
reaction that occurs after consuming a specific food [1]. FA affects up to 10% of the
population with the highest rates in children [2–4], and incidence appears to be increasing
along with other atopic disorders [3,5]. Clearly FA is a growing healthcare concern, yet
effective treatment other than strict dietary avoidance remains elusive [1]. Over the past
decade, several small clinical studies of two different therapeutic approaches, oral
immunotherapy (OIT) and sublingual immunotherapy (SLIT), have shown promising
results. In this review, we discuss recent findings of randomized controlled trials (RCT)
evaluating the efficacy and safety of OIT and SLIT, and then present potential strategies for
improving food immunotherapy.
Immunotherapy trials for FA
Immunotherapy involves manipulating the immune response directed against an antigen.
Subjects who tolerate and successfully complete food immunotherapy protocols can
experience two possible outcomes. The first is desensitization, where continuous allergen
exposure increases the threshold of clinical reactivity to the food. The second and more ideal
outcome is clinical tolerance, which is defined as the ability to consume a food without
allergic symptoms after treatment is ceased indefinitely. It is unknown whether ‘tolerance’
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after immunotherapy resembles the natural tolerance that occurs spontaneously for some FA
patients, or if therapeutic tolerance is mechanistically similar to classical immune tolerance.
For this reason, the term ‘sustained unresponsiveness’ has been introduced into the literature
to avoid confusion [6••]. How such a change develops in humans is incompletely
understood, but possibly involves the generation of allergen-specific regulatory T cells
(Treg) or deletion of effector T cells [7,8]. Other immunological changes described in
desensitized patients include decreased allergen-specific IgE but increased specific IgG4,
and diminished mast cell and basophil activity [6,9,10,11•,12•].
OIT
OIT comprises the daily consumption of milligrams to grams of allergen, typically mixed
with a food vehicle, which is incrementally increased over weeks to months with the goal of
inducing desensitization and ultimately tolerance. Open-label pilot studies involving patients
with milk, egg, and peanut allergies had suggested that OIT could increase the threshold of
clinical reactivity to the culprit food [10,13–15]. Recent RCT have provided further
compelling evidence that OIT can frequently induce desensitization in patients with FA
[6,9,12•], although the effect varies across studies (Table 1).
There is evidence that OIT can also result in clinical tolerance or sustained
unresponsiveness. In 2012, Keet et al. reported that 40% of subjects receiving milk OIT
passed an OFC when treatment was ceased for 6 weeks [16•], although it is possible that
some may have naturally outgrown their FA. That same year, a study by the Consortium for
FA Research (CoFAR) found that of 30 patients desensitized with egg OIT, eleven (27.5%
of the active treatment group) passed on OFC after halting therapy for 4–6 weeks [6••].
These individuals continued to consume egg regularly without problems when surveyed 12
months later. The likelihood of spontaneous FA resolution was very low in this study, and
none of the control subjects exhibited evidence of outgrowing their egg sensitivity. This
landmark article was the first to suggest that OIT could be a truly disease-modifying
treatment.
SLIT
SLIT involves placement of micrograms to milligrams of allergen under the tongue with
doses that are up to 1000-fold less than OIT. A few RCT have investigated allergen-specific
SLIT for patients with milk [16•], peanut [11•,17•], hazelnut [18] and peach allergies [19],
demonstrating varying degrees of efficacy (Table 1). One of the most informative studies to
date was a CoFAR-sponsored multicenter RCT for peanut SLIT involving forty subjects.
After 44 weeks of therapy, 70% of patients receiving SLIT developed partial desensitization
to peanut, compared to only 15% of the placebo group (P < 0.001). These findings were
slightly inferior to a prior single center study of peanut SLIT [11•], indicating the
importance of performing multicenter trials to more accurately assess treatment effect.
One randomized study attempted to directly compare the efficacy of OIT and SLIT for the
treatment of cow’s milk allergy [16•]. After an initial dose escalation with SLIT, 30 subjects
were randomized to continue either daily SLIT or begin OIT at two different maintenance
doses. Sixty weeks later, 70% of subjects in the OIT group passed a milk OFC, compared to
only 10% in the SLIT group. The apparent superior efficacy of OIT was mitigated by a
higher rate of systemic reactions during therapy. A retrospective comparison study of
peanut-allergic individuals treated with either peanut OIT or SLIT also found greater
efficacy associated with the former [20]. Thus, OIT may prove to be more efficacious than
SLIT, but this could come at the expense of safety.
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Summary of clinical trials
Some general conclusions can be drawn from the few published RCT for OIT and SLIT.
First, a very small number of individuals have been subjected to rigorous study, thus
restricting the generalizability of reported findings. Of those treated with OIT, greater than
80% experience at least partial desensitization to the food allergen while on therapy.
Complete desensitization, which can be conservatively defined as passing a 5 g OFC
without symptoms [21], occurs in 45–75% of OIT subjects. The rate is even lower for SLIT,
with few subjects reaching full desensitization during the blinded phases of the trials. Only a
minority of OIT subjects (25–40%) develops a state that resembles clinical tolerance; thus,
prolonged and potentially indefinite therapy may be needed to provide adequate protection
for most patients. The safety profile of OIT and SLIT is also less than ideal. Treatment-
related adverse events are relatively frequent and reactions requiring epinephrine appear to
occur more often when compared to the practice of dietary avoidance [22]. There have also
been isolated reports of new eosinophilic gastrointestinal disorders developing in individuals
receiving OIT [23]. Lastly, nearly all studies have excluded patients with severe food-
induced anaphylaxis, which is the population in most need of effective interventions. Given
these limitations, it is not surprising that two recent Cochrane reviews of OIT for milk [24•]
and peanut [25] allergies found insufficient evidence to support its clinical implementation,
which is in accordance with current clinical guidelines [1]. With the many uncertainties
surrounding the long-termefficacy and safety of OIT and SLIT, we share the opinion of
other leading researchers that food immunotherapy remains in a state of clinical equipoise
[26•].
Strategies for enhancing food immunotherapy
OIT and SLIT are promising treatments for FA, but it is unlikely that current protocols will
be effective for all patients, especially those with a more severe phenotype. The next
generation of food immunotherapy should seek to further increase the likelihood of
developing long-term tolerance while minimizing adverse events associated with treatment.
Three general strategies for improving immunotherapy include firstly modifying the
immunological characteristics of the food allergen, secondly adjunct treatment with
immunomodulatory agents, and lastly utilizing alternative antigen delivery schemes (Figure
1). A variety of interventions that address these areas have been proposed, many of which
are already being tested in the clinical setting.
Modification of food allergens
Altering the molecular structure of food allergens to decrease their allergenicity, while
maintaining their immunotherapeutic effect, is an attractive approach for improving the
safety of immunotherapy. Extensive heating is a straightforward method for changing the
allergenicity of some foods (e.g. milk and eggs), as it results in the loss of conformational
epitopes recognized by IgE [27]. A large proportion of patients allergic to milk or eggs
tolerate the foods in baked forms [28,29], and two recent studies suggest that routine
consumption of extensively heated food allergens can accelerate allergy resolution. In the
first study, milk-allergic subjects able to add baked milk to their diets were 16-fold more
likely to develop complete milk tolerance compared to a matched observational cohort that
avoided all milk products [30•]. Similar results were observed for egg-allergic patients who
incorporated baked egg into their diets [31]. The use of heat-denatured allergens in OIT and
SLIT could lead to fewer treatment-related adverse events, a notion that requires further
investigation.
A more targeted approach for decreasing allergenicity is to genetically alter the
immunodominant B cell epitopes. Point mutagenesis of specific amino acids within the
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major peanut allergens Ara h 1–3 substantially decreased recognition when blotted with
pooled peanut-specific IgE from allergic human volunteers [32]. Treatment of peanut-
sensitized mice with heat-killed Escherichia coli expressing these engineered recombinant
peanut allergens was protective against peanut-induced anaphylaxis [33]. On the basis of
these encouraging animal studies, a phase I clinical trial was performed using rectal
administration of a similar product. Unfortunately, 5 of 10 subjects had to withdraw from
the study due to treatment-related adverse events [34]. Successfully engineering
recombinant hypoallergenic food allergens for use in immunotherapy trials might require
individualized approaches, a labor-intensive process that may limit clinical feasibility.
Adjunct therapy with immunomodulatory agents
Altering the immune environment to prevent Th2-mediated responses directed against
immunotherapeutic agents is another approach for reducing adverse events during OIT and
SLIT. In this regard, agents that inhibit IgE-mediated signaling pathways, such as the
monoclonal antibody omalizumab, could improve the safety of food immunotherapy. Anti-
IgE monotherapy for peanut allergy could increase the sensitivity threshold for a subset of
patients [35], but was associated with an unacceptably high rate of severe adverse reactions
in a recent phase II trial [36]. Therefore, using omalizumab as an adjunct to OIT or SLIT
may be a safer and more effective strategy. Accordingly, Nadeau and colleagues
investigated the utility of using omalizumab to facilitate desensitization in a small group of
children undergoing high-dose milk OIT [37•]. After 9 weeks of pretreatment with
omalizumab, 9 of the 11 patients initially enrolled were able to rapidly reach maintenance
dosing with minimal adverse events. Several small trials combining omalizumab treatment
and OIT for other food allergens are currently underway (ClinicalTrials.gov, NCT01510626,
NCT01157117, NCT00932282).
An herbal formulation (FAHF-2) containing nine herbs used in traditional Chinese medicine
is being evaluated as a possible treatment for FA. In preclinical studies, FAHF-2 had
multiple immunomodulatory effects and protected mice from peanut-induced anaphylaxis
[38,39]. Subsequent phase I trials in patients with FA have shown FAHF-2 to be well
tolerated with minimal side effects [40,41]. Whether FAHF-2 would have synergistic effects
when combined with OIT or SLIT is currently unknown.
Other immunomodulatory strategies for improving FA immunotherapy include the use of
Th1-promoting adjuvants [42], helminth therapy [43], and monoclonal antibodies directed
against cytokines associated with Th2-mediated inflammation [44]. While it is possible that
biological agents alone will be efficacious treatments for FA, combining them with allergen-
specific immunotherapy protocols may be a more effective approach that warrants further
investigation.
Alternative allergen delivery strategies
It is possible that the gut mucosa in FA patients is fundamentally altered to promote allergic
responses against ingested antigens, and therefore delivering allergens to other tissues may
prove more effective for generating tolerance. Accordingly, epicutaneous immunotherapy
(EPIT), which involves the application of an allergen-loaded patch on intact skin, was
shown to modestly desensitize milk allergic patients in a small RCT [45]. These findings
have prompted further clinical inquiries into the efficacy of EPIT for the treatment of FA
(ClinicalTrials.gov, NCT01170286, NCT01197053).
The use of nanoparticles for allergen delivery is a developing area that could be directly
applicable to OIT and SLIT. Nanoparticles can be designed to target dendritic cells, which
are important for inducing regulatory T cells. They can also be engineered to provide a
Moran et al. Page 4













sustained release of antigen, thus obviating the need for daily dosing [46]. Nanoparticles
containing peanut proteins were recently generated and tested in mice, and induced a greater
Th1 response than protein alone [47]. These preliminary findings will hopefully lead to
more extensive studies regarding the use of nanotechnology for allergen immunotherapy.
Conclusions
The past decade has been an exciting period in the area of FA research, as studies regarding
OIT and SLIT provide hope that an effective therapy for FA is within reach. Given the
encouraging results from small clinical trials, it is understandable why some are advocating
strongly for immediate implementation of OIT and SLIT for the treatment for FA. However,
definitive evidence of safety and efficacy are lacking with the current immunotherapeutic
strategies for FA, and more research is needed before these therapies can be offered to
patients in routine clinical practice. The next generation of food immunotherapies will
hopefully build upon the early success of OIT and SLIT, and help make an emerging
treatment into the standard of care.
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Strategies for improving food immunotherapy. Modification of food allergens to reduce
recognition by IgE can be accomplished by extensive heating or molecular alteration of
immunodominant epitopes. Incorporation of food allergens into nanoparticles or
epicutaneous delivery of antigen could improve immunotherapy efficacy while reducing
treatment-associated adverse reactions. Finally, adjunct use of immunomodulatory agents
may prevent allergic responses mediated by allergen-specific T helper (TH) cells, and
promote tolerance through induction of T cell anergy or development of regulatory T cells.
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